Advanced search
Publication Cover
Cogent Medicine Volume 4, 2017 - Issue 1
Journal homepage
1,134
Views
3
CrossRef citations to date
0
Altmetric
Case Report

Being aware of potentially fatal interstitial lung disease in patients with head and neck cancer treated with concurrent cetuximab and radiotherapy

Mari ShimadaDepartment of Otolaryngology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi329-0498, JapanCorrespondence[email protected]
View further author information
,
Hiroshi NishinoDepartment of Otolaryngology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi329-0498, JapanView further author information
,
Toru SasakiDepartment of Otolaryngology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi329-0498, JapanView further author information
,
Takafumi NagatomoDepartment of Otolaryngology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi329-0498, JapanView further author information
&
Hirofumi FujiiDepartment of Oncology, Jichi Medical University, Shimotsuke, Tochigi, JapanView further author information
|
Udo SchumacherUniversity Medical Center Hamburg-Eppendorf, GermanyView further author information
(Reviewing Editor)
Article: 1284419 | Received 30 Oct 2016, Accepted 16 Jan 2017, Published online: 01 Feb 2017

References

  • Chua, W., Peters, M., Loneragan, R., & Clarke, S. (2009). Cetuximab-associated pulmonary toxicity. Clinical Colorectal Cancer, 8, 118–120.10.3816/CCC.2009.n.019
  • Erbitux (Cetuximab). (2013). [Package insert]. Princeton, NJ: Bristol-Myers Squibb.
  • Hattori, N., & Kohno, N. (2011). KL-6. Mebio, 28, 38–46.
  • Inomata, M., & Azuma, A. (2012). Interstitial Pneumonia. Kokyu (Respiratory), 31, 1028–1033.
  • Keishi, K., Arata, A., Minoru, K., Hideto, K., Masahiko, K., & Akihiko, G. (2013). Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respiratory Investigation, 51, 260–277.
  • Lauren, T., & Tamera, C. (2015). Interstitial lung disease in 2015: where are we now? Thorax, 44, 546–552.
  • Lenz, H. J. (2006). Anti-EGFR mechanism of action: Antitumor effect and underlying cause of adverse events. Oncology, 20, 5–10.
  • Ohnishi, H., Yokoyama, A., & Yasuhara, Y. (2003). Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax, 58, 872–875.10.1136/thorax.58.10.872
  • Ohtsuki, Y., Nakanishi, N., & Fujita, J. (2007). Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias. Medical Molecular Morphology, 40, 163–167.10.1007/s00795-007-0360-0

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.